Question mark on efficacy of generic drugs

Once upon a time Ranbaxy kept the Indian pharmaceuticals industry's flag flying high with the name it carved out for itself on the back of a burgeoning manufacturing and trading of generic medicines. All of that came crashing down with the US FDA (Food and Drugs Administration agency) calling it out for questionable / dubious business practices and quality standards, the associated out of courts settlement, subsequent legal battles with Daiichi (the Japanese company that took over Ranbaxy and later sued its founders for selling it a lemon) and now the book by an investigative journalist called Katherine Eban.

This book called 'A Bottle of Lies' chronicles the run-ins with US FDA that Ranbaxy had, detailing out how the company top management engaged in misrepresentation and manipulation of data to get through quality checks etc. and its consequent impact on public health. Dinesh Thakur, who was the chief whistleblower at Ranbaxy and on whose citings the above book is based on, recently gave a lecture on this topic. A link to the same is given below.

https://www.moneylife.in/article/why-india-cant-produce-best-quality-generic-drugs-asks-dinesh-thakur-the-ranbaxy-whistleblower/58252.html

This entire saga has brought a cloud over the pharmaceutical industry in India and its cosy nexus with regulators who seemingly are not doing a good job of providing oversight.